Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association.
Level 5 - mechanism / opinion, no new human data
AHA Presidential Advisory representing expert consensus and narrative framework without original empirical data
PubMed 37807924 · doi:10.1161/CIR.0000000000001184
What was done
This American Heart Association presidential advisory establishes a clinical framework for cardiovascular-kidney-metabolic (CKM) health. It synthesizes evidence across cardiology, nephrology, and endocrinology to define CKM syndrome, outline a life-course staging construct, propose risk-prediction approaches, and recommend harmonized, interdisciplinary care models that incorporate social determinants of health.
What was found
The abstract provides no quantitative data or numerical estimates. It qualitatively describes CKM health as the pathophysiological interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system, noting a high population burden of poor CKM health (particularly in socioeconomically disadvantaged groups) and emphasizing the availability of newer multi-target therapies with combined cardioprotective, kidney, and metabolic benefits.
Why it matters
It formally establishes CKM syndrome as a unified clinical entity, encouraging earlier risk-stage identification and integrated cross-specialty management to prevent multi-organ morbidity and cardiovascular mortality.
Limits
As an expert presidential advisory and consensus statement, this paper presents clinical frameworks rather than new empirical data, a meta-analysis, or a systematic review. The abstract reports no statistical outcomes, effect sizes, or validation metrics for the proposed staging and prediction models.
Cited by
- supports Medical literature has recognized cardiovascular-kidney-metabolic syndrome, acknowledging that cardiovascular disease, heart attacks, and strokes are driven by metabolic disease.